OLYMPUS CORP/S (OTCMKTS:OCPNY) Shares Cross Above 200-Day Moving Average of $0.00

OLYMPUS CORP/S (OTCMKTS:OCPNY) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.00 and traded as high as $11.18. OLYMPUS CORP/S shares last traded at $10.93, with a volume of 530 shares changing hands.

A number of research analysts recently commented on the stock. Zacks Investment Research downgraded shares of OLYMPUS CORP/S from a “buy” rating to a “hold” rating in a research report on Tuesday, June 18th. ValuEngine downgraded shares of OLYMPUS CORP/S from a “buy” rating to a “hold” rating in a research report on Tuesday, April 9th.

The company has a debt-to-equity ratio of 0.27, a current ratio of 1.59 and a quick ratio of 1.05. The firm has a market capitalization of $15.08 billion, a P/E ratio of 221.00, a PEG ratio of 2.34 and a beta of 0.70. The stock has a 50-day simple moving average of $11.56.


Olympus Corporation manufactures and sells precision machineries and instruments worldwide. The company operates through four segments: Medical Business, Scientific Solutions Business, Imaging Business, and Others. It offers endoscopic video endoscopy systems, endoscopic ultrasound systems, ultrasound endoscopes and probes, endoscopic ultrasound observation devices, capsule endoscopy systems, integrated documentation systems, therapeutic equipment, and ancillary products; cleaning, disinfecting, and sterilization systems; gastrointestinal, colono, duodeno, and broncho endoscopes; endoscopy products for gastroenterological surgery, bronchial surgery, urology, gynecology, orthopedic surgery, neurosurgery, and anesthesiology, as well as ear, nose, and throat; and therapeutic and surgical equipment, endoscope ancillary equipment, and endotherapy devices.

Read More: Balanced Fund

Receive News & Ratings for OLYMPUS CORP/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OLYMPUS CORP/S and related companies with MarketBeat.com's FREE daily email newsletter.